The board has a date. That milestone may be tied to your next financing round, a commitment to investors, or a development plan with little room to slip.
The team needs a path.
Every sponsor eventually hears a milestone committed before the plan behind it exists. Say the board has announced first patient dosed by 31 March, meaning the day a participant receives study drug at an activated site. Precision matters here, because “first patient” can mean screened, consented, or dosed, and those events can sit weeks apart.
The date itself rarely needs defending. What the team needs is a shared account of how we reach it: the assumptions the plan rests on, the dependencies outside our control, the tradeoffs we are prepared to make, and the dates by which leadership must decide. Pressure to deliver and clarity about delivery are different things, and a sponsor needs both. Pressure tells the team the milestone is important, and clarity tells them what has to be true along the way for it to happen.
The language makes the difference. “We cannot make March” invites a debate about ambition. “We can make March if the protocol is final by 15 November” invites a decision, and it is every bit as ambitious. A team can be confident about a demanding date once it can see the road to it.
Those are different paths to the milestone, even when the proposed dates look the same.
This is where the board’s deadline needs to become a CRO-selection conversation, not simply a requirement in the RFP, and this is the conversation ABRA Clinical Consulting supports. Our Clinical Trial Readiness Check starts by defining the date, then maps what stands between the sponsor and that date, so the next board meeting begins with a plan that matches the commitment.
The board has given us a date, and we hand back a path that everyone can understand.
